Article Versions Notes

Su Y-K, Bamodu OA, Su I-C, Pikatan NW, Fong I-H, Lee W-H, Yeh C-T, Chiu H-Y, Lin C-M. Combined Treatment with Acalabrutinib and Rapamycin Inhibits Glioma Stem Cells and Promotes Vascular Normalization by Downregulating BTK/mTOR/VEGF Signaling. Pharmaceuticals. 2021; 14(9):876. https://doi.org/10.3390/ph14090876

Su, Yu-Kai, Oluwaseun Adebayo Bamodu, I-Chang Su, Narpati Wesa Pikatan, Iat-Hang Fong, Wei-Hwa Lee, Chi-Tai Yeh, Hsiao-Yean Chiu, and Chien-Min Lin. 2021. "Combined Treatment with Acalabrutinib and Rapamycin Inhibits Glioma Stem Cells and Promotes Vascular Normalization by Downregulating BTK/mTOR/VEGF Signaling" Pharmaceuticals 14, no. 9: 876. https://doi.org/10.3390/ph14090876

Su, Y.-K., Bamodu, O. A., Su, I.-C., Pikatan, N. W., Fong, I.-H., Lee, W.-H., Yeh, C.-T., Chiu, H.-Y., & Lin, C.-M. (2021). Combined Treatment with Acalabrutinib and Rapamycin Inhibits Glioma Stem Cells and Promotes Vascular Normalization by Downregulating BTK/mTOR/VEGF Signaling. Pharmaceuticals, 14(9), 876. https://doi.org/10.3390/ph14090876